Medical/Pharmaceuticals
NUH's Smallest Surviving Baby Discharged Well to Home
SINGAPORE, Aug. 7, 2021 /PRNewswire/ -- Kwek Yu Xuan is a 14-month-old infant who had undergone and survived an incredible life battle when she first came into the world. Born prematurely at 212 grams on9 June 2020, in the midst of the global COVID-19 pandemic, this small and fragile baby had a l...
2021-08-07 15:00
3655
FibroBiologics Announces Inaugural Board of Directors
Company Announces Formation of Board of Directors HOUSTON, Aug. 6, 2021 /PRNewswire/ -- FibroBiologics, a clinical stage company developing fibroblast-based therapeutic solutions for chronic diseases, announced today the formation of its Board of Directors. Leading this group is Chairman,Pete ...
2021-08-06 22:01
3196
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial
SHENZHEN, China, Aug. 6, 2021 /PRNewswire/ -- ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval from National Medical Products Administration (" NMPA") for clinical trial for treatments using intravenous adminis...
2021-08-06 19:50
2992
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
HONG KONG, Aug. 5, 2021 /PRNewswire/ -- Akeso, Inc. (9926.HK, the "Company" or "Akeso") announced that the anti PD-1 monoclonal antibody drugPenpulimab monoclonal antibody injection co-developed by the Company with Sino Biopharmaceutical Limited (stock code: 1177.HK), has obtained marketing appr...
2021-08-06 09:39
29128
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval
HAIKOU, China, Aug. 5, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the result...
2021-08-05 21:00
27277
Berry Oncology Completes Series B1 Funding, Attracting Most Venture Capital to Date in Early Cancer Screening Sector
BEIJING, Aug. 5, 2021 /PRNewswire/ -- Berry Oncology Corporation, a member company ofChina's leading early cancer screening firm Berry Genomics, yesterday on its 4th anniversary, announced the completion of a US$99.15 million Series B1 financing round. This brings the total capital raised by the ...
2021-08-05 21:00
2580
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
SYDNEY, Aug. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBP...
2021-08-05 18:00
1982
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody
* South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment * ABL's third IND this year for bispecific antibody therapeutics SEONGNAM, South Korea, Aug. 4, 2021 /PRNewswire/ -- ABL Bio, Inc...
2021-08-04 21:30
2675
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's
MELBOURNE, Australia, Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Of...
2021-08-04 20:39
25522
Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®
SEOUL, South Korea, Aug. 3, 2021 /PRNewswire/ -- Yuyu Pharma, a pharmaceutical company based in Korea, and Novartis Korea announced today that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lami...
2021-08-03 21:00
2665
Pulnovo Medical, a pioneer medical device company, specializing in the treatment of pulmonary artery hypertension, recently raised millions of dollars through OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures(LAV), and GaoRong Capital
NANJING, China, Aug. 3, 2021 /PRNewswire/ -- Pulnovo Medical, a pioneer medical device company, specializing in the treatment of pulmonary artery hypertension, recently raised millions of dollars through OrbiMed, Cenova, Lilly Asia Ventures (LAV), and GaoRong Capital. Funds raised in this round w...
2021-08-03 20:32
2615
111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China
SHANGHAI, Aug. 3, 2021 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced a strategic cooperation agreement with Suzhou Zelgen ...
2021-08-03 20:00
8385
TCM Lianhua Qingwen shows stable in vitro antiviral effect on the Delta variant: Expert
GUANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- The latest research findings from the team of Professor Yang Zifeng from the State Key Laboratory of Respiratory Disease inGuangzhou, China, have showed that Chinese medicine Lianhua Qingwen has an effective inhibitory action on the Delta variant of ...
2021-08-03 15:27
3113
Cardinal Health completes sale of Cordis business to Hellman & Friedman
DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health's Cordis business to H&F. The sale price of approximately$1 billion includes the buyer's assumption of certain lia...
2021-08-02 23:00
4414
Bionomics Announces Plans to Conduct U.S. Initial Public Offering
ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United ...
2021-08-02 18:00
14570
BIOKANGTAI COVID-19 Vaccine Approved for Phase III Clinical Trial in the Philippines
SHENZHEN, China, Aug. 2, 2021 /PRNewswire/ -- On July 30, Shenzhen Kangtai Biological Products Co., Ltd. (BIOKANGTAI) was approved by the Philippine Food and Drug Administration (PFDA) to launch the phase III clinical trial of its independently developed Inactivated COVID-19 Vaccine (Vero cells) ...
2021-08-02 15:25
5979
LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic
SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH). ...
2021-08-02 11:11
1840
Appendix 4C - Q4 FY21 Quarterly Cash Flow Report
Highlights: * Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial * Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model * Presents to MST Access Australian Micro & Small Caps Conference ...
2021-07-30 21:05
15575
China Jo-Jo Drugstores Completes Redomiciliation Merger
HANGZHOU, China, July 30, 2021 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that th...
2021-07-30 21:00
15546
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
* Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimer's Disease SHANGHAI and GAITHERSBURG, Md., July 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage bio...
2021-07-30 20:00
9299
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 301 media titles]
2026-05-19 18:10
Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 291 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 287 media titles]
2026-05-18 15:30
Amity's Singapore-Headquartered AI Research Center Wins Gold at Taiwan's 2026 Best AI Awards
[Picked up by 282 media titles]
2026-05-13 08:00
Herbalife and Cristiano Ronaldo Bring Performance Nutrition to Everyday Routines with "Fuel Like Ronaldo" Campaign
[Picked up by 281 media titles]
2026-05-13 15:00
Most Read
H World Group Reports Q1 Results, Highlighting Asset-light Growth and Expanding APAC Footprint
2026-05-15 20:11
7319
